Methods of reducing the risk of cardiovascular events in a subject

HK40038229BActive Publication Date: 2026-07-10AMARIN PHARMACEUTICALS IRELAND LIMITED(IE)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Patents
Current Assignee / Owner
AMARIN PHARMACEUTICALS IRELAND LIMITED(IE)
Filing Date
2021-03-23
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Existing treatments for cardiovascular diseases, such as Lovaza®, can increase LDL-C and/or non-HDL-C levels in some patients, necessitating improved methods to reduce cardiovascular risk, particularly in subjects on statin therapy with elevated triglyceride levels.

Method used

Administering a pharmaceutical composition containing eicosapentaenoic acid ethyl ester (EPA) or its derivatives to subjects at a dose-equivalent to 4 g of EPA per day, which reduces cardiovascular events by 25-30% over five years, as demonstrated in clinical trials.

Benefits of technology

The use of eicosapentaenoic acid ethyl ester significantly reduces the risk of cardiovascular events by 25-30% over five years, including reductions in myocardial infarctions, strokes, and coronary revascularizations, without influencing baseline triglyceride levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000107_0000
    Figure 00000107_0000
  • Figure 00000108_0000
    Figure 00000108_0000
  • Figure 00000109_0000
    Figure 00000109_0000
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.